An interventional study of transcranial direct current stimulation (tDCS) in Parkinson's Disease, sponsored by Inje University. Withdrawn at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Inje University · Not applicable, Interventional, and Treatment
We cannot enroll the participants
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Parkinson Disease with a site in Korea, Republic of — 13 open to participants now, 15 under way, 1 of them phase 3. Parkinson Disease · Korea, Republic of.
Among the 76 studies in Parkinson Disease with a site in Korea, Republic of, this one is the 67th largest by enrollment of the 67 interventional ones that give a count, is the only one that started in 2019, is one of 28 with no phase, and was the 41st registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →13 of the 76 studies in Parkinson Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Innopeutics Corporation · Sites in Korea, Republic of
Ages 50–80
Innopeutics Corporation · Sites in Korea, Republic of
Ages 50–80
Hoffmann-La Roche · Sites in Korea, Republic of, United States, Australia and 14 more countries
Ages 50–85
Pusan National University Yangsan Hospital · Sites in Korea, Republic of
Ages 40+
Samsung Medical Center · Sites in Korea, Republic of
Ages 50+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 9 · Phase 4 16
First in 2006; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 60 across the 67 interventional studies, 500 across the 9 observational. Of the 45 that completed or were terminated, 12 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 76 have an industry lead sponsor. The 10 most frequent:
Inje University is the lead sponsor of 93 studies on the registry; 1 is open to participants now.
Inje University has 2 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Parkinson Disease with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07569133Ho-Won LeeEfficacy of Repetitive Transcranial Magnetic Stimulation for Improving Depressive Symptoms in Patients With Parkinson's Disease | 2026-11-27 |
| NCT07522138Seoul National University HospitalHome-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study | 2026-12-01 |
| NCT01799915NYU Langone HealthNatural History Study of Synucleinopathies | 2026-12-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 76 studies in Parkinson Disease with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Depression is common in Parkinson's disease (PD), but the effective treatment is not established yet. tDCS is a non-invasive brain stimulation to modulate brain function. The tDCS on the depression in general population were already conducted, but not in PD. This study is to know whether transcranial direct current stimulation (tDCS) is effective for the treatment of depression in PD. Participant will be asked to visit three consecutive days for the non-invasive stimulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Constant weak electric currents through scalp via two electrodes will be delivered. * Current intensity: 2mA, 20min/day
Device: transcranial direct current stimulation (tDCS)
* a 1 mA current, for 30 s giving an initial sensation of tDCS while minimizing stimulatory effects * Ramp up and ramp down was over 10 s. (Ref. Loo CK et al., Br J Psychiatry 2012;200:52-9)
Device: transcranial direct current stimulation (tDCS)
tDCS is one of non-invasive brain stimulation. Constant, low current is delivered to the specific brain areas to change brain plasticity.
BDI score
The changes of Beck depression inventory after tDCS
Time frame: (1) before the1st visit (within one month) (2) right after the 3rd tDCS (3) within one months after the 3rd tDCS
HDRS score
The changes of Hamilton Depression Rating Scale after tDCS
Time frame: (1) before the 1st visit (within one month) (2) right after 3rd tDCS, within 24 hours (3) within one months after the 3rd tDCS
MADRS score
The changes of Mongomery-Asberg Depression Rating Scale after tDCS
Time frame: (1) before the 1st visit (within one month) (2) right after the 3rd tDCS, within 24 hours (3) within one months after 3rd tDCS
resting state functional MRI
The changes of resting state functional MRI after tDCS
Time frame: (1) before the 1st visit (within one month) (2) after the 3rd tDCS, within 24 hours (on the same day as the 3rd tDCS)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2019; primary completion for Dec 2020, 22 months later.
How these figures are worked out, and which studies are left out of them.
We cannot enroll the participants
We cannot enroll the participants
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Inje University